LG AI Research has partnered with D&D Pharmatech to push the boundaries of oral peptide drug development using AI technology.
The collaboration aims to revolutionize drug discovery by integrating LG's advanced AI capabilities with D&D's expertise in peptide development. This partnership was formalized at a signing ceremony in Seoul, attended by executives from both companies. Woohyung Lim from LG AI Research emphasized that this initiative is not just about technology adoption; it represents a strategic move to create specialized AI solutions that tackle the intricate challenges of drug discovery.
Peptides, which are crucial for various physiological functions, have typically been administered through injections due to their instability in the gastrointestinal tract. The joint project seeks to develop oral formulations for peptide therapeutics, significantly enhancing safety and absorption while reducing development timelines and costs through AI-driven design technologies. D&D Pharmatech will focus on validating and advancing the drug candidates generated by LG AI Research, creating a feedback loop to continuously optimize the AI models involved.
Beyond this partnership, LG AI Research is expanding its "Biology AI" portfolio, which includes initiatives like the Cancer Agentic AI platform for personalized oncology solutions. This platform aims to expedite biopsy analysis from weeks to real-time, showcasing the potential of AI to transform both clinical and pharmaceutical processes. As LG positions itself at the intersection of AI and biotechnology, the implications for both drug discovery and patient care appear promising, potentially reshaping industry standards.